We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

PROMEGA

Promega has a portfolio of more than 3,000 products covering the fields of genomics, protein analysis and expression,... read more Featured Products: More products

Download Mobile App




Intestinal Microbiota Determines the Risk of MDRO Acquisition

By LabMedica International staff writers
Posted on 10 Feb 2022

Colonization and infection by multidrug-resistant organisms (MDRO) remains a public health problem. This is particularly important in intensive care units (ICUs) where the risk of MDRO acquisition/colonization results from the selective pressure associated with prolonged broad-spectrum antibiotic treatment.

Control initiatives consist in detecting patients at high risk of MDRO acquisition, implementation of antibiotic stewardship programs, epidemiological surveillance to detect MDRO intestinal carriage, microbiological tests to rapidly identify MDRO and use of effective measures to reduce their nosocomial transmission.

Clinical Microbiologists at the Hospital Clínic de Barcelona (Barcelona, Spain) conducted a prospective study including patients admitted to a 12-bed ICU between July-December 2018. Rectal swabs to detect MDRO intestinal colonization were obtained at ICU admission and weekly thereafter during ICU-stay. Patients were classified into three groups according to MDRO colonization status. Control group included patients who were not colonized by MDROs at ICU admission and did not get colonized during ICU stay.

The team extracted DNA using the PureLink Microbiome DNA Purification kit (Invitrogen, Carlsbad, MA, USA) and quantified using Quantus Flurometer (Promega, Madison, WI, USA). The 16S rRNA gene sequencing was performed on 138 rectal swabs from 62 patients using the sequenced using Illumina MiSeq platform (Illumina, San Diego, CA, USA). After sequence filtering and sample rarefaction alpha and beta diversity indices were obtained using QIIME2 and statistical analyses were performed.

The investigators reported that of the patients studied, 19/62 (30.65%) presented MDRO colonization at admission, 16/62 (25.81%) were colonized during stay and 27/62 (43.55%) were not colonized; 45/62 (72.58%) developed an infection and mortality was 29.03%. Higher bacterial diversity and abundance of Bacillales Family XI incertae sedis and Prevotella families were associated with lower risk of colonization by MDRO, infection and death while Enterococcaceae family was associated with increased risk of infection and death. The lasso regression and the multivariate analysis identified Family XI incertae sedis to be associated with lower risk of infection (OR=0.997) and microbial evenness index to be associated with lower mortality (OR=0.68) risk.

The authors concluded that microbial diversity and abundance of certain bacterial taxa could have prognostic value in patients admitted to a critical care unit. Larger perspective studies should address the value of these markers in clinical practice. The study was published on January 19, 2022 in the journal Clinical Microbiology and Infection.


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Troponin I Test
Quidel Triage Troponin I Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.